ANI Pharmaceuticals’ (ANIP) Buy Rating Reiterated at Guggenheim

ANI Pharmaceuticals (NASDAQ:ANIP)‘s stock had its “buy” rating reiterated by equities researchers at Guggenheim in a report issued on Tuesday, Benzinga reports. They currently have a $77.00 price target on the specialty pharmaceutical company’s stock. Guggenheim’s price target indicates a potential upside of 16.09% from the stock’s previous close.

A number of other equities analysts have also issued reports on ANIP. Capital One Financial assumed coverage on shares of ANI Pharmaceuticals in a research report on Friday, March 15th. They set an “overweight” rating and a $80.00 target price on the stock. Truist Financial boosted their price target on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a report on Friday, March 1st. Finally, HC Wainwright boosted their price target on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a report on Monday, March 4th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $80.00.

ANI Pharmaceuticals Stock Up 1.1 %

NASDAQ ANIP traded up $0.71 during trading on Tuesday, reaching $66.33. The company’s stock had a trading volume of 28,356 shares, compared to its average volume of 137,650. The company has a current ratio of 3.57, a quick ratio of 2.81 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $1.40 billion, a PE ratio of 78.66 and a beta of 0.79. The business has a 50-day moving average price of $65.12 and a 200-day moving average price of $58.70. ANI Pharmaceuticals has a 1-year low of $36.99 and a 1-year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a net margin of 3.86% and a return on equity of 18.06%. The business had revenue of $131.65 million during the quarter, compared to analysts’ expectations of $123.02 million. On average, research analysts forecast that ANI Pharmaceuticals will post 3.55 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, COO Muthusamy Shanmugam sold 10,093 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $65.35, for a total transaction of $659,577.55. Following the transaction, the chief operating officer now owns 872,527 shares in the company, valued at approximately $57,019,639.45. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, COO Muthusamy Shanmugam sold 10,093 shares of the stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $65.35, for a total value of $659,577.55. Following the sale, the chief operating officer now directly owns 872,527 shares in the company, valued at approximately $57,019,639.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Nikhil Lalwani sold 28,965 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $65.52, for a total transaction of $1,897,786.80. Following the completion of the sale, the chief executive officer now owns 444,981 shares in the company, valued at $29,155,155.12. The disclosure for this sale can be found here. Insiders have sold a total of 156,803 shares of company stock worth $10,363,466 in the last 90 days. Corporate insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. lifted its holdings in ANI Pharmaceuticals by 93.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 248 shares during the last quarter. BluePath Capital Management LLC acquired a new stake in ANI Pharmaceuticals during the 3rd quarter valued at $34,000. Pacer Advisors Inc. acquired a new stake in ANI Pharmaceuticals during the 4th quarter valued at $41,000. AJOVista LLC acquired a new stake in ANI Pharmaceuticals during the 4th quarter valued at $58,000. Finally, ADAR1 Capital Management LLC acquired a new stake in ANI Pharmaceuticals during the 4th quarter valued at $132,000. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.